Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Companion Diagnostics

Yoshiya Oda's Biography

Yoshiya Oda, President, Eisai Inc

Dr. Yoshiya Oda received his BS, MS and Ph.D. degree in Pharmaceutical Science from Kyoto University (Japan). He is working in Eisai (Japanese pharmaceutical company) for 25 years. At the same time, Dr. Oda also served as an associate professor at Medical Institute of Bioregulation in Kyushu University, Graduate School of Medicine at the University of Tokyo and as a professor at Graduate School of Medicine at Chiba University. Dr. Oda has published 76 original papers, 46 review papers and book chapters, and 139 invited lecture (27 international seminars). Among them, Dr. Oda has made several major contributions to the field of proteomics including metabolic stable isotope labeling method for quantitative proteomics. Dr. ODA has received several awards: Research Award from the Society of Chromatographic Sciences, Japan (1999), Division Award from Pharmaceutical Research Vision in the Pharmaceutical Society of Japan (2005), Research Award from the Mass Spectrometry Society of Japan (2005), and Nature-Invitrogen Award (2006). Dr. Oda is currently leading Biomarkers & Personalized Medicine Core Function Unit in Eisai. Dr. Oda has also established preclinical imaging facility in Eisai. The primary purpose of his biomarker group is to provide “Personalized Medicine” to patients and their families. His group contributes to enhance the accuracy of product creation delivering the right products to the right patients based on biomarkers. He believes that biomarkers enable the rapid decision-making with scientific rationales at discovery and early clinical stage, and biomarkers enhance the speed of product creation during the entire drug development process. His group oversees biomarker activity during discovery stage, development stage and clinical stage. Their core technologies are genomics (array, quantitative PCR, nano-String, Ion torrent PGM, siRNA screening, miRNA etc), proteomics/metabolomics (ELISA, multiplex assay, mass spectrometry, HPLC etc), preclinical imaging (MRI, PET, SPECT, CT and optical imaging), tissue/biofluid banking (LIMS, IHC, ISH, Flow cytometer etc) and bioinformatics. He has also in vitro diagnostic group in Japan to develop diagnostic kits for regulatory approval.

Yoshiya Oda Image

Discovery & Development of Circulating Biomarkers for Drug Development

Tuesday, 28 October 2014 at 09:15

Add to Calendar ▼2014-10-28 09:15:002014-10-28 10:15:00Europe/LondonDiscovery and Development of Circulating Biomarkers for Drug

Biomarkers play important roles for drug development, because (1) biomarkers can show target engagement (proof of mechanism) of drug candidates, (2) biomarkers can determine right dosage and dosing schedule (pharmacodynamic biomarkers), (3) biomarkers can identify responders/poor responders for drug candidates (patient stratification), and (4) biomarkers can monitor drug responses (drug monitoring). Disease target tissue analysis is common in oncology area, but we cannot always get archival tissue samples when we need. Especially it may be hard to obtain tissues samples when our drug is used as 3rd line therapy. In addition, we sometimes need clinical samples from both pre- and post-dosing. Body fluid samples such as plasma, serum, urine would be ideal for biomarker analysis, because it is relatively easy to obtain samples during clinical studies, even multiple time points. Proteins, endogenous metabolites and miRNAs are interesting as circulating biomarkers among different disease areas. During the conference, I would like to show some examples from our data, and discuss current challenges such as: How to obtain clinical relevant samples for preclinical studies? How to show scientific rationale about drug efficacy/patient stratification biomarkers? How to determine the cut-off values? When is a good time to start the development of companion diagnostics?

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion